Neurodegenerative Disease

NOVATO, California, July 13, 2026 Lighthouse Pharmaceuticals has announced new clinical findings from its Phase 2/3 GAIN trial, demonstrating...

CARLSBAD, California, July 13, 2026 ALZpath, Inc. has announced a major scientific milestone at the Alzheimer’s Association International Conference...

MENLO PARK, California, July 13, 2026 PharmatrophiX, in collaboration with Indiana University School of Medicine, has presented encouraging new...

ROCHESTER, N.Y., July 8, 2026 Vaccinex announced that it will present new biomarker findings from its Phase 1b/2 SIGNAL-AD...

CervoMed, BOSTON, July 9, 2026 CervoMed Inc. has announced the successful completion of enrollment in its Phase 2a clinical...

NEW YORK | July 9, 2026 Apertura Gene Therapy, a biotechnology company developing next-generation adeno-associated virus (AAV) capsids for...

SAN FRANCISCO | July 9, 2026 Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced...

STOCKHOLM, Sweden, July 1, 2026 AlzeCure Pharma AB has announced a landmark global out-licensing and collaboration agreement with Danish...

BETHESDA, Md., June 29, 2026 Gain Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...

SAN DIEGO, June 30, 2026 Aspen Neuroscience, Inc. has announced the successful completion of Cohort 3 and Cohort 4...